Anti-retroviral drug hepatotoxicity and risk factors in HIV Patients with or without Hepatitis B and C : a review
Loading...
Date
2015
Authors
Wambani, J.R.
Ogola, P.E.
Arika, W.M.
Rachuonyo, H.O.
Kemboi, N.G.
Lihana, R.
Burugu, M.W.
Journal Title
Journal ISSN
Volume Title
Publisher
Adis, Springer Healthcare
Abstract
Physicians are treating patients infected with human immunodeficiency virus and/or hepatitis B or hepatitis C in
their practice more often. Long-term complications of this diseases are multifactorial and can be related to the virus
itself or to adverse effects of antiretroviral therapy. The liver is the main organ for regulating the internal environment
of a body. There is no way to compensate for the loss of a liver function. It has major influences on the flow of
nutrients as well as controlling carbohydrate, protein and fat metabolism. Drugs are significant in causing liver injury.
More than nine hundred drugs, herbs and toxins have been documented as being hepatotoxic in line with different
risk factors. The incidences of severe hepatic injury vary among different study cohorts as well as the differences in
risk factors. Patients with a co-infection of HIV and Hepatitis B or C are at a risk of getting liver injury from
antiretroviral drugs because the co-infections accelerate liver injury that may lead to cirrhosis or hepatocellular
carcinoma. The risk of liver damage for those with a monoinfection of HIV alone is lower than in co-infections. This
review explores risk factors for hepatotoxicity, its hepatotoxic antiretroviral drugs and the mechanisms of toxicity. It is
meant to highlight the hepatotoxic potential of different antiretroviral drugs currently in use by HIV infected
individuals
Description
Research paper
Keywords
Hepatotoxicity, Antiretroviral drugs, Risk factors, Mechanisms, Hepatitis B, Hepatitis C, Hepatotoxic potential, Coinfections
Citation
Wambani JR, Ogola PE, Arika WM, Rachuonyo HO, Kemboi NG, et al. (2015) Anti-Retroviral Drug Hepatotoxicity and Risk Factors in HIV Patients with or Without Hepatitis B and C: A Review. J Infect Dis Ther 3: 258. doi:10.4172/2332-0877.1000258